Effects of clinicopathological factors on prognosis of young patients with resected breast cancer

Wen Li, MD, Yunfu Deng, MD, Qiang Wu, MD, Wenjie Chen, MD, Zhengkun Liu, MD, Ting Wang, MD, Cheng Ai, MD, Fang Chen, MD, Zhu Wang, MD, Guangzhi Ma, MD, Qinghua Zhou, MD

Abstract
This study aims to analyze the relationship between clinicopathological characteristics and survival in young patients (≤35 years old) with resected breast cancer. A total of 173 cases were included in this study. The clinicopathological factors potentially associated with prognosis were evaluated. Furthermore, we categorized patients into different groups to evaluate the prognosis according to hormone receptor status or important risk factors.

Younger age (≤30 years) was an independent predictor for poor disease-free survival (DFS) and overall survival (OS). Besides, PR negative status, tumor grade, and advanced lymph nodes postsurgery were independent prognostic factors of DFS, while PR negative status and advanced lymph nodes postsurgery were independent prognostic factors of OS. For hormone receptor-positive patients, people with ER+ or PR+ and HER2−/− showed poorer prognosis than the other 2 levels. Risk factor grouping based on the ER, PR, HER2, Ki-67 status, tumor grade, and lymph nodes postsurgery showed that patients in highest score group received the poorest prognosis. Grading system based on the hormone status or the risk factor grouping may offer a useful approach to assess which subgroups of young breast cancer present poorer prognosis.

Abbreviations: BCS = breast-conserving surgery, CIs = confidence intervals, DFS = disease-free survival, ER = estrogen receptor, HER2 = human epidermal growth factor receptor 2, HR = hazard ratios, OS = overall survival, PR = progesterone receptor, TNBC = triple-negative breast cancer.

Keywords: young age, breast cancer, prognosis, molecular subtypes, survival

1. Introduction
Breast cancer, one of the most commonly diagnosed cancer in women worldwide, affects more than 1.3 million individuals and accounts for about 14% of cancer-related deaths.

Approximately 6.6% of breast cancer patients are diagnosed in women younger than 40 years, 2.4% in those younger than 35, and 0.65% in those younger than 30. In China, the reported cases in women younger than 35 years are markedly higher than those in western countries.

Moreover, the increase in young breast cancer patients is highly problematic, and the behavior of these tumors is more aggressive.

Young women with breast cancer are likely to present advanced stages at diagnosis, including higher histologic grade, larger tumor size, more aggressive pathological characteristics, and higher rates of recurrence at any clinical stage in comparison with their older counterparts.

Although several large-scale studies have reported that young age (≤35) is an independent prognostic factor for both disease-free survival (DFS) and overall survival (OS), few studies focus on the impact of clinical and pathologic factors on the prognosis in young breast cancer patients. This study aims to evaluate the prognostic significance of clinicopathological factors stratified by age, surgery type, molecular subtype based on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) statuses. In addition, considering that hormone receptor-positive breast cancer is the main subtype in young patients, we divide hormone receptor-positive breast cancer into different groups to assess the prognostic influence on young patients.

2. Materials and methods
2.1. Patients and follow-up
A total of 1796 patients with histologically confirmed breast cancer with surgical resection in West China Hospital of Sichuan University were confirmed from 2010 to 2012. Among these patients, a total of 173 patients younger than age 35 without distant metastasis at first diagnosis were included in this retrospective study. Patients were investigated and followed up every 3 months for 3 years, every 6 months for 5 years, and every
12 months in 6 to 10 years after operation. The examination of carcinoembryonic antigen (CEA) and carbohydrate antigen 153 (CA153), breast ultrasound, and mammography, liver ultrasound, chest X-ray, head CT scanning, and gynecological examination were included. This study was approved by the Research Ethics Committee of West China Hospital of Sichuan University, all procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study, and all the patients provided written informed consent before enrollment. All the authors attested that the trial was conducted in accordance with the protocol and all its amendments and with Good Clinical Practice standards.

2.2. Pathology methods

The expression of ER, PR, HER2, and Ki-67 were tested by immunohistochemical staining. The following primary antibodies were applied: monoclonal ER antibody (clone SP1; Ventana, Tucson, AZ, USA), monoclonal PR (clone 1E2; Ventana), Ki-67 (clone 30-9; Ventana), and HER2 (clone 4B5; Roche, Sandhofer, Mannheim, Germany). The cut-off value of positive ER/PR was defined as ≥1% within immunoreactive tumor cell nuclei. The cut-off value of high Ki-67 was ≥14%. The immunohistochemical staining for HER2 was scored as 0, 1+, 2+, or 3+; 3+ was considered as HER2 overexpression, 0 or 1+ was defined as HER2 negative, and 2+ was equivocal. Fluorescence in situ hybridization (FISH) testing was needed for explicit HER2 gene amplification status. All staining specimens were independently viewed and scored by 2 pathologists in West China Hospital, Sichuan University.

2.3. Molecular subtypes and treatment

Molecular subtypes were classified as Luminal A (ER+ and/or PR+, HER2-; Ki-67 <14), Luminal B (HER2-) (ER+ and/or PR+, HER2-; Ki-67 ≥14), Luminal B (HER2+) (ER+ and/or PR+, HER2-), any Ki-67, HER2-enriched (ER-, PR+, HER2+), any Ki-67, and triple-negative (ER−, PR−, HER2−, any Ki-67) breast cancer (TNBC) in accordance with the St Gallen expert consensus of 2013.[10] Postoperative patients with hormone receptor positive and Ki-67 <14% received adjuvant endocrine therapy for 5 years, while patients who were hormone receptor positive and Ki-67 ≥14% underwent chemotherapy and endocrine therapy. HER2+ patients received Trastuzumab and chemotherapy, while TNBC received chemotherapy. Patients who were positive for axillary lymph node postsurgery (n ≥3) or underwent breast conserving surgery received postoperative radiotherapy.

2.4. Classification of hormone receptor and assessment of risk factor scores

Breast cancer patients are treated according to ER and HER2 status in clinical setting. ER+ tumors typically respond to hormone therapy, and HER2+ tumors respond to anti-HER2 therapy. Given its nature as a highly heterogeneous disease with different histology, gene expression profiles, or mutation, hormone-positive breast cancer usually presents various clinical courses and responses to systemic treatment.[31] PR is another molecular marker that may be used in the clinic as loss of PR in ER+ tumors is thought to be predictive for the lack of response to hormone therapy.[31] Besides, variability in Ki-67 scoring is observed in several of the world’s most experienced laboratories and significant interobserver variability is detected due to limited analytical validity.[12] According to a previous study, we hereby classified hormone receptor-positive breast cancer as level 1 (ER+ or PR+, HER2−), level 2 (ER+, PR+, HER2+), or level 3 (ER+ or PR+, HER2−/−) based on the ER, PR, and HER2 status and regardless of the expression of Ki-67.[3] Patients with level 2 and level 3 tumors were considered to be at a more aggressive state and were treated with more chemotherapy than level 1, while level 1 subgroup received more endocrine therapy than the other 2 levels.

A total of 173 patients were divided into 3 groups based on the scores of important risk factors including ER, PR, HER2, and Ki-67 status (ER−, PR−, and HER2+, and Ki-67+, 1 point each), tumor grade (grade 1 was considered as 1 point, and so on), and lymph nodes postsurgery (0 for no positive node, 1 for 1–3 positive nodes, 2 for 4–9 positive nodes, and 3 for ≥10 positive nodes). Group 1 was scored 1–4, group 2 was scored 5–6, and group 3 was scored 7–10, respectively.

2.5. Statistical analysis

DFS was defined as the time from diagnosis to the date of disease relapse, death, or last follow-up. OS was calculated from the time of diagnosis to death as a result of recurrence events or last follow-up, whichever occurred first. The follow-up deadline was March 2018. The relationship between the different age groups and the clinicopathological factors was analyzed by χ² test. The end-points were estimated using the Kaplan–Meier method, and the differences between survival curves were tested using the log rank test. Univariate and multivariate analyses with the Cox proportional hazard regression model were performed to assess the influence of potential confounders on DFS and OS. The crude hazard ratios (HR) and corresponding 95% confidence intervals (CIs) were reported. Statistical analyses were performed using the SPSS (version 20.0) software package (SPSS Inc., Chicago, IL). P < .05 was considered statistically significant.

3. Results

3.1. Clinicopathological factors and outcome

According to the 2013 St. Gallen expert consensus, the molecular subtypes of all the 173 cases were divided into 5 types: 27 cases were classified into luminal A subtype (15.6%), 57 cases into luminal B (HER2-) subtype (32.9%), 38 cases into luminal B (HER2+) subtype (22.0%), 19 cases into HER2 subtype (11.0%), and 32 cases into TNBC subtype (18.5%). With 128 (74.0%) patients undergoing mastectomy and 45 (26.0%) patients received breast-conserving surgery (BCS). The median age of all patients was 32, within median follow-up time of 64 months. Tumor relapse occurred in 59 cases, among which 42 cases died. The clinical and pathologic characteristics of the 173 patients included in this study were shown in Table 1. In univariate analysis, PR status, tumor grade, lymph nodes postsurgery, and histological grade were significantly associated with DFS and OS. In addition, patients younger than 30 was associated with significantly shorter DFS and OS, compared with patients aged from 30 to 35 (P = .016 and P = .011, respectively, Table 1,
As shown in Table 4, in multivariate analysis, patient age \((P=.002)\), PR status \((P=.042)\), tumor grade \((P=.012)\), and lymph nodes postsurgery \((P<.001)\) were independent predictors of DFS for young patients, and patient age \((P=.002)\), PR status \((P=.003)\), and lymph nodes postsurgery \((P=.002)\) were correlated with OS. In both univariate and multivariate analyses, the classification of patient age was an independent predictor for DFS and OS (Fig. 1A and B, and Tables 2 and 4), indicating that patients younger than 30 showed a poorer prognosis compared with patients aged 31 to 35. We also analyzed the clinical and pathologic factors between the 2 groups at diagnosis, as shown in Table 2, the expression levels of...
ER, PR, HER2, and Ki-67, tumor size, lymph nodes postsurgery, molecular subtype, and treatment condition did not display any difference between women aged 31 to 35 and women younger than 30 years.

3.2. Local therapy, age, and survival

We evaluated the effect of surgery type, including BCS and mastectomy, on DFS and OS in young patients with T1-T2N0-N +M0 breast cancer. A total of 146 patients were considered, with 101 patients undergoing mastectomy and 45 undergoing BCS. No connection was observed between surgery type and cumulative probability of DFS ($P = .120$) or OS ($P = .140$). Moreover, the effectiveness of surgery type stratified by age on DFS and OS was analyzed. Compared with patients aged 30 to 35 years, patients below 30 years of age were associated with lower DFS after mastectomy ($P = .007$) but not associated with OS ($P = .204$). No statistically significant difference in DFS or OS after BCS was observed between patients aged from 31 to 35 and patients younger than 30 years old ($P = .345$, and $P = .755$, respectively).

3.3. Prognosis and receptor-positive breast cancer or risk factors grouping

The hormone receptor levels were 1, 2, and 3 in 59 (48.4%), 24 (19.7%), and 39 (32.0%) of the 122 patients with hormone receptor-positive breast cancer, respectively. In univariate analysis, hormone receptor level was an independent prognostic factor for both DFS and OS ($P = .002$; Fig. 2A, 2B, Table 3). Young breast cancer patients with ER+, PR+, and HER2– received the best prognosis, whereas the group of ER+ or PR+, HER2–/+ patients had the poorest prognosis in hormone receptor-positive patients. In the present study, the risk factor group based on ER, PR, HER2, and Ki-67 status, tumor grade, and lymph nodes postsurgery were 1, 2, and 3 in 125 (72.3%), 38 (22%), and 10 (5.8%) of the 173 patients, respectively. Patients in risk group 3 were predicted to present the poorest DFS and OS ($P < .001$; Fig. 3A, 3B, Table 3). All of the 10 patients in group 3 progressed, and 8 patients died. In multivariate analysis, hormone receptor level was an independent prognostic factor for DFS ($P = .038$), and the risk factor group was an interrelated prognostic predictor of DFS and OS in young patients ($P = .006$, and $P = .010$, respectively; Table 4).

4. Discussion

Previous studies have shown that young age (≤35 years old) is an adverse prognostic factor for women with breast cancer. Moreover, compared with older patients, younger breast cancer patients present later disease stage, higher grade tumors (poorer and more undifferentiated tumors), and poorer receptor status.[13,14] However, relatively few studies focused on the prognostic effect of clinicopathologic factors among young breast cancer patients. In the present study, we selected several common clinical and pathological factors, including patient age, ER, PR, HER2, Ki-67 status, tumor histological grade, tumor grade, lymph nodes postsurgery, molecular subtype, and treatment condition, which were possible predictors of cancer outcomes. The results implied that patient age, PR status, tumor grade, and lymph nodes postsurgery were associated with DFS, while patient age, PR status and lymph nodes postsurgery were associated with OS. Older age (30–35) suggested better prognosis, whereas PR negative status, large tumor grade, and advanced lymph nodes postsurgery were associated with poorer prognosis.

It has been generally recognized that young age itself is an independent risk factor for recurrence and death. A study based on a national population cancer registry showed that young age is an independent risk factor for death (HR = 1.095).[15] Peng et al.[16] retrospectively analyzed a large cohort of 511 young breast cancer patients aged ≤35 years by comparing clinicopathological characteristics with a cohort of 551 older patients aged from 35 to 50 years old, and their results showed that younger patients present significantly shorter DFS than their older counterparts (median 23.2 months vs 28.4 months, $P = .024$). A trial referring to age ≤40 years as young breast
### Table 2
Patient and tumor characteristics by age group.

| Total | ≤30 | 30–35 | P   |
|-------|-----|-------|-----|
|       |     |       |     |
| Family history |     |       |     |
| Yes   | 27  (15.6%) | 10  (17.5%) | 17  (14.7%) | .623 |
| No    | 146 (84.4%) | 47  (82.5%) | 99  (85.3%) |     |
| ER+   | 57  | 116   |     |
| PR+   | 85  (49.1%) | 28  (49.1%) | 57  (49.1%) | .999 |
| HER2+ | 42  (24.3%) | 18  (31.6%) | 24  (20.7%) | .116 |
|       | 131 (75.7%) | 39  (68.4%) | 92  (79.3%) |     |
| <30   | 59  (48.4%) | 22  (43.4%) | 37  (41.1%) | .514 |
| ≥30   | 116 (51.6%) | 52  (56.6%) | 79  (58.9%) |     |
| pT Stage |     |       |     |
| 1     | 65  (37.6%) | 29  (50.9%) | 36  (51.7%) | .778 |
| 2     | 81  (46.8%) | 21  (36.8%) | 59  (31.0%) |     |
| 3     | 22  (12.7%) | 6   (10.5%) | 16  (13.8%) |     |
| 4     | 5   (2.9%)  | 1   (1.8%)  | 4   (5.4%)  |     |
| pN Stage |     |       |     |
| 0     | 75  (43.4%) | 28  (49.1%) | 47  (40.5%) | .635 |
| 1     | 52  (30.1%) | 15  (26.3%) | 37  (31.9%) |     |
| 2     | 33  (19.1%) | 9   (15.8%) | 24  (20.7%) |     |
| 3     | 13  (75.1%) | 5   (8.8%)  | 8   (6.9%)  |     |
| Molecular subtype |     |       |     |
| Luminal A | 27  (15.6%) | 8   (14.0%) | 19  (17.2%) | .887 |
| Luminal B (HER2-) | 57  (32.9%) | 17  (29.8%) | 40  (31.0%) |     |
| Luminal B (HER2+) | 38  (22.0%) | 15  (26.3%) | 23  (21.6%) |     |
| HER2-enriched | 19  (57.8%) | 6   (10.5%) | 9   (7.8%)  |     |
| TNBC  | 32  (18.5%) | 11  (19.3%) | 21  (22.4%) |     |
| Histological grade |     |       |     |
| I     | 118 (68.2%) | 37  (64.9%) | 81  (69.8%) | .056 |
| II    | 32  (17.7%) | 10  (16.9%) | 22  (19.0%) |     |
| III   | 55  (31.8%) | 20  (35.1%) | 35  (30.2%) |     |
| Surgery type |     |       |     |
| Mastectomy | 128 (74.0%) | 37  (64.9%) | 91  (78.4%) | .007 |
| BCS   | 45  (26.0%) | 20  (35.1%) | 25  (21.6%) |     |
| Chemotherapy |     |       |     |
| Yes   | 143 (82.7%) | 51  (89.5%) | 92  (79.3%) | .348 |
| No    | 30  (17.3%) | 6   (10.5%) | 24  (20.7%) |     |
| Hormonal therapy |     |       |     |
| Yes   | 137 (79.2%) | 43  (75.4%) | 94  (81.0%) | .906 |
| No    | 36  (20.8%) | 14  (24.6%) | 22  (19.0%) |     |
| Radiotherapy |     |       |     |
| Yes   | 82  (47.4%) | 27  (47.4%) | 55  (47.4%) | .204 |
| No    | 91  (52.6%) | 30  (52.6%) | 61  (52.3%) |     |
| Target therapy |     |       |     |
| Yes   | 25  (14.5%) | 11  (19.3%) | 14  (12.1%) | .002 |
| No    | 148 (85.5%) | 46  (80.7%) | 102 (87.9%) |     |

BCS = breast conserving surgery, TNBC = triple-negative breast cancer.

### Table 3
ER, PR, and HER2 status or risk factors grouping with outcomes.

| Total | Relapse | Died | DFS | OS |
|-------|---------|------|-----|----|
|       |         |      | P   | HR (95%CI) | P   | HR (95%CI) |
| ER, PR, and HER2 status | 122 | 43 | 29 | .002 | 1.779 (1.232–3.701) | .002 | 2.356 (1.825–4.857) |
| ER+, PR+, HER2− | 50 (48.4%) | 13 (30.2%) | 6  (20.7%) |     |
| ER+, PR+, HER2+ | 24 (19.7%) | 8  (18.6%) | 7  (24.1%) | .002 | 3.658 (1.2570–6.239) | .001 | 3.852 (2.084–5.962) |
| ER+/PR+, HER2− | 32 (20.7%) | 22 (51.2%) | 16 (51.2%) |     |
| Risk factors grouping | 173 | 59 | 42 | <.001 |
| 1     | 125 (22.0%) | 27  (45.8%) | 16  (38.1%) |     |
| 2     | 30  (15.6%) | 22  (37.3%) | 18  (34.9%) |     |
| 3     | 18  (10.5%) | 10  (53.9%) | 8   (44.4%) |     |

DFS = disease-free survival, OS: overall survival.
cancer revealed that patient age of younger than 35 years (as opposed to 35–40) was an independent risk factor for poorer local relapse-free survival, DFS, and OS.[17] Moreover, Zhao et al,[3] reported that patients who were younger than 30 presented poorer prognosis compared with patients aged from 31 to 35. In our study, patient age showed a significant correlation with both DFS and OS in young patients, and patients younger than 30 years of age showed an adverse prognosis compared with patients aged from 31 to 35; this finding was consistent with those of the previous study. Moreover, the results showed no difference between age and clinicopathological factors in the 2 groups when classified by age; again, these results were consisted with those of a previous study.[17]

**Table 4**

| Outcome | Variables                          | P    | HR (95%CI)       |
|---------|-----------------------------------|------|-----------------|
| DFS     | Age (30–35)                       | .002 | 0.429 (0.248–0.742) |
|         | PR status (negative)              | .042 | 1.757 (1.019–3.021) |
|         | Tumor grade (pT)                  | .012 | 1.843 (1.612–3.660) |
|         | Lymph nodes postsurgery (pN+)     | <.001| 2.427 (1.536–3.835) |
|         | ER, PR, and HER2 Status           | .038 | 1.786 (1.254–3.568) |
|         | Risk factors grouping             | .066 | 1.818 (1.185–2.791) |
| OS      | Age (30–35)                       | .002 | 0.354 (0.185–0.678) |
|         | PR status (negative)              | .003 | 2.825 (1.406–5.587) |
|         | Lymph nodes postsurgery (pN+)     | .002 | 2.493 (1.410–4.469) |
|         | Risk factors grouping             | .010 | 1.993 (1.171–3.539) |

DFS = disease-free survival, OS = overall survival.

**Figure 2.** ER, PR, HER2 status and survival. Kaplan–Meier survival analysis on DFS (A) in accordance with ER, PR, and HER2 status. Kaplan–Meier survival analysis on OS (B) in accordance with ER, PR, and HER2 status.

**Figure 3.** Risk factor grouping and survival: DFS by Kaplan–Meier survival analysis (A) in accordance with risk factor grouping. OS by Kaplan–Meier survival analysis (B) in accordance with risk factor grouping.
Given that young women with breast cancer are known to have a higher risk of local recurrence and mortality, the impact of surgical treatment on outcomes in young breast cancer patients remains unclear, and BCS in young patients remains to be a controversial issue. Several studies suggested that young women (younger than 35 or 40 years) showed inferior outcomes with BCS, implying that these women might be better served by mastectomy. Quan et al. reported similar oncologic outcomes in a cohort of young women (≤35) who were selected for treatment with BCS and mastectomy. Besides, a meta-analysis carried out on 22,598 patients showed that mastectomy unlikely provides better OS compared to BCS in early young breast cancer patients. In the present study, our results demonstrated no differences in DFS and OS between BCS and mastectomy in young breast cancer patients. When surgery type was stratified by age, compared with patients aged from 30 to 35 years, patients aged ≤30 years was associated with lower DFS after mastectomy but not associated with OS. These results might suggest that BCS was a rational surgery type for young women. It was worth noting that patients included in this cohort had 84.4% T1/T2 tumors, but only 45 cases (26.0%) received BCS. A nationwide survey indicated that in developed urban areas in China, BCS was performed on only 24.3% in 2008, which was much lower compared with western countries. One explanation for this was the lack of resources for radiation therapy, especially in less developed regions in China. Hence readers should be cautious referring to the result considering the limited patient number that received BCS.

PR is known to be regulated by the estrogen receptor α (ERα), and loss of PR expression indicates a more aggressive disease phenotype, which is less dependent on estrogen signaling. A previous study observed that a negative PR status occurred more frequently in young breast cancer patients. Mohammed et al. reported that PR was an anti-proliferative factor in an estrogen-driven context. Besides, PR* status distinctly improved outcome prediction over ER status alone for patients who received adjuvant endocrine therapy, and several studies confirmed that the absence of PR was an independent risk factor for DFS or OS. In our study, we detected that PR negative status was an independent risk factor and was significantly associated with a more unfavorable DFS and OS in both univariate and multivariate analyses. By contrast, ER expression was not typically related with prognosis, as was consistent with the results of previous studies.

The molecular subtypes of breast cancer are considered to reflect tumor biology and exert a vital influence on prognosis. Patients with luminal A subtype are likely to receive the best prognosis than the other 3 subtypes. The proportion distribution of molecular subtypes is different in young breast cancer patients and, young breast cancer patients present a higher rate of triple-negative and HER2 overexpression subtypes compared with the older patients. Villarreal-Garza et al. reported that young women diagnosed with hormone receptor-positive breast cancer in Mexico were more specifically categorized as luminal B, experiencing poor survival outcomes. In our study, IHC surrogate for luminal B was the most common, account for more than half of all cases. Moreover, considering that hormone receptor-positive breast cancer remained to be the major subtype among young patients, we categorized the hormone-positive breast cancer into 3 levels, and the results showed that ER+, PR+, HER2—/ demonstrated no differences in DFS and OS between BCS and mastectomy in young breast cancer patients. When surgery type was stratified by age, compared with patients aged from 30 to 35 years, patients aged ≤30 years was associated with lower DFS after mastectomy but not associated with OS. These results might suggest that BCS was a rational surgery type for young women. It was worth noting that patients included in this cohort had 84.4% T1/T2 tumors, but only 45 cases (26.0%) received BCS. A nationwide survey indicated that in developed urban areas in China, BCS was performed on only 24.3% in 2008, which was much lower compared with western countries. One explanation for this was the lack of resources for radiation therapy, especially in less developed regions in China. Hence readers should be cautious referring to the result considering the limited patient number that received BCS.

PR is known to be regulated by the estrogen receptor α (ERα), and loss of PR expression indicates a more aggressive disease phenotype, which is less dependent on estrogen signaling. A previous study observed that a negative PR status occurred more frequently in young breast cancer patients. Mohammed et al. reported that PR was an anti-proliferative factor in an estrogen-driven context. Besides, PR* status distinctly improved outcome prediction over ER status alone for patients who received adjuvant endocrine therapy, and several studies confirmed that the absence of PR was an independent risk factor for DFS or OS. In our study, we detected that PR negative status was an independent risk factor and was significantly associated with a more unfavorable DFS and OS in both univariate and multivariate analyses. By contrast, ER expression was not typically related with prognosis, as was consistent with the results of previous studies.

The molecular subtypes of breast cancer are considered to reflect tumor biology and exert a vital influence on prognosis. Patients with luminal A subtype are likely to receive the best prognosis than the other 3 subtypes. The proportion distribution of molecular subtypes is different in young breast cancer patients and, young breast cancer patients present a higher rate of triple-negative and HER2 overexpression subtypes compared with the older patients. Villarreal-Garza et al. reported that young women diagnosed with hormone receptor-positive breast cancer in Mexico were more specifically categorized as luminal B, experiencing poor survival outcomes. In our study, IHC surrogate for luminal B was the most common, account for more than half of all cases. Moreover, considering that hormone receptor-positive breast cancer remained to be the major subtype among young patients, we categorized the hormone-positive breast cancer into 3 levels, and the results showed that ER+, PR+, HER2—/ exhibited the poorest prognosis among the 3 subtypes. ER, PR, HER2, and Ki-67 status, tumor grade, and axillary lymph nodes involved postsurgery are combined to determine a prognostic parameter. In our study, the risk factor-based combination classification was divided into 3 groups, and the result revealed that the risk score group was an independent prognostic predictor, with the risk of disease progression and death increasing by 1.818 and 1.953 times, respectively. This finding indicated that the risk grouping score might be helpful in selecting patient subgroups for further adjuvant treatment.

5. Conclusions
In conclusion, this study shows that compared with their older counterparts, patients younger than 30 years at diagnosis with breast cancer constitute an independent risk factor for decreased DFS and OS among young patients (≤35 years); moreover, the grading system based on hormone level and risk factor grouping may serve a useful index for evaluating the risk of breast cancer in young women.

Acknowledgments
We thank all practitioners who participated in the documentation of the data.

Author contributions
Data curation: Wenjie Chen.
Formal analysis: Wen Li, Guangzhi Ma.
Funding acquisition: Ting Wang.
Investigation: Ting Wang.
Methodology: Qiang Wu, Fang Chen, Zhu Wang.
Software: Yunfu Deng.
Validation: Zhengkun Liu.
Visualization: Qinghua Zhou.
Writing – original draft: Wen Li, Yunfu Deng, Wenjie Chen, Cheng Ai, Guangzhi Ma.
Writing – review & editing: Qinghua Zhou.

References
[1] Wu J, Xue X, Zhang B, et al. Enhanced antitumor activity and attenuated cardiotoxicity of Epirubicin combined with Paonol against breast cancer. Tumour Biol 2016;37:12301–13.
[2] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA 2015;65:87–108.
[3] Zhao Y, Dong X, Li R, et al. Correlation between clinical-pathologic factors and long-term follow-up in young breast cancer patients. Transl Oncol 2015;8:263–72.
[4] Chen HL, Ding A, Wang FW. Prognostic effect analysis of molecular subtype on young breast cancer patients. Chin J Cancer Res 2015;27:428–36.
[5] Azim HA, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res 2014;16:427.
[6] Lee HB, Han W. Unique features of young age breast cancer and its management. J Breast Cancer 2014;17:301–7.
[7] Anastasiadi Z, Lianos GD, Ignatiadou E, et al. Breast cancer in young women: an overview. Updates Surg 2017;69:313–7.
[8] Jia X, Liu G, Mo M, et al. Reproductive factors and hormone receptor status among very young (<35 years) breast cancer patients. Oncotarget 2015;6:24571–80.
[9] Anders CK, Fan C, Parker JS, et al. Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol 2011;29:e18–20.

7
Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013;24:2206–23.

Creighton CJ. The molecular profile of luminal B breast cancer. Biologics 2012;6:289–97.

Polley MY, Leung SC, McShane LM, et al. An international Ki67 reproducibility study. J Natl Cancer Inst 2013;105:1897–906.

Gnerlich JL, Deshpande AD, Jeffe DB, et al. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg 2009;208:341–7.

Maggard MA, O’Connell JB, Lane KE, et al. Do young breast cancer patients have worse outcomes? J Surg Res 2003;113:109–13.

Anders CK, Hsu DS, Broadwater G, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008;26:3324–30.

Peng R, Wang S, Shi Y, et al. Patients 35 years old or younger with operable breast cancer are more at risk for relapse and survival: a retrospective matched case-control study. Breast 2011;20:568–73.

Ordu C, McGuire K, Alex G, et al. The prognostic impact of molecular subtypes and very young age on breast conserving surgery in early stage breast cancer. Cureus 2016;8:e633.

Quan ML, Paszat LF, Fernandes KA, et al. The effect of surgery type on survival and recurrence in very young women with breast cancer. J Surg Oncol 2017;115:122–30.

Voogd AC, Nielsen M, Peterse JL, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 2001;19:1688–97.

Vla J, Gandini S, Gentilini O. Overall survival according to type of surgery in young (<40 years) early breast cancer patients: a systematic meta-analysis comparing breast-conserving surgery versus mastectomy. Breast 2015;24:173–81.

Yuan XM, Wang N, Ouyang T, et al. Current status of diagnosis and treatment of primary breast cancer in Beijing, 2008. Chin J Cancer Res 2011;23:38–42.

Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol 2014;15:e279–89.

Colleoni M, Rotmensz N, Robertson C, et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 2002;13:273–9.

Mohammed H, Russell IA, Stark R, et al. Progesterone receptor modulates ERLapha action in breast cancer. Nature 2015;523:313–7.

Bardou VJ, Arpino G, Edlidge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21:1973–9.

Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:746–52.

Villarreal-Garza C, Mohar A, Bargallo-Rocha JE, et al. Molecular subtypes and prognosis in young mexican women with breast cancer. Clin Breast Cancer 2017;17:e95–102.

Keegan TH, DeRouen MC, Press DJ, et al. Occurrence of breast cancer subtypes in adolescent and young adult women. Breast Cancer Res 2012;14:R35.